159 related articles for article (PubMed ID: 21883029)
1. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms.
Johansson P; Mesa R; Scherber R; Abelsson J; Samuelsson J; Birgegård G; Andréasson B
Leuk Lymphoma; 2012 Mar; 53(3):441-4. PubMed ID: 21883029
[TBL] [Abstract][Full Text] [Related]
2. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
3. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.
Abelsson J; Andréasson B; Samuelsson J; Hultcrantz M; Ejerblad E; Johansson B; Emanuel R; Mesa R; Johansson P
Leuk Lymphoma; 2013 Oct; 54(10):2226-30. PubMed ID: 23398206
[TBL] [Abstract][Full Text] [Related]
4. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
Scherber R; Dueck AC; Johansson P; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferarri ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Harrison CN; Radia D; Mesa RA
Blood; 2011 Jul; 118(2):401-8. PubMed ID: 21536863
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
[TBL] [Abstract][Full Text] [Related]
6. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Geyer HL; Kosiorek H; Dueck AC; Scherber R; Slot S; Zweegman S; Te Boekhorst PA; Senyak Z; Schouten HC; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Cannon K; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA
Haematologica; 2017 Jan; 102(1):85-93. PubMed ID: 27540137
[TBL] [Abstract][Full Text] [Related]
7. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Langlais BT; Mazza GL; Kosiorek HE; Palmer J; Mesa R; Dueck AC
J Hematol; 2021 Oct; 10(5):207-211. PubMed ID: 34804309
[TBL] [Abstract][Full Text] [Related]
8. Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire.
Găman MA; Scherber RM; Ursuleac I; Crişan AM; Bădeliţă SN; Ionescu BO; Ghiaur AE; Brînză M; Pîrciulescu N; Lascăr TO; Diaconu CC; Găman AM; Coriu D
J Clin Med; 2024 Jun; 13(11):. PubMed ID: 38892995
[No Abstract] [Full Text] [Related]
9. Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care.
Christensen SF; Scherber RM; Mazza GL; Dueck AC; Brochmann N; Andersen CL; Hasselbalch HC; Mesa RA; Geyer HL
BMC Cancer; 2021 Jun; 21(1):691. PubMed ID: 34112113
[TBL] [Abstract][Full Text] [Related]
10. The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.
Gowin K; Langlais BT; Kosiorek HE; Dueck A; Millstine D; Huberty J; Eckert R; Mesa RA
Cancer Med; 2020 Dec; 9(24):9445-9453. PubMed ID: 33140580
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.
Anderson LA; James G; Duncombe AS; Mesa R; Scherber R; Dueck AC; de Vocht F; Clarke M; McMullin MF
Am J Hematol; 2015 Oct; 90(10):864-70. PubMed ID: 26113113
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in MPN comes of age as a therapeutic target.
Scherber RM; Geyer HL; Mesa RA
Curr Hematol Malig Rep; 2014 Dec; 9(4):324-30. PubMed ID: 25262210
[TBL] [Abstract][Full Text] [Related]
13. Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.
Padrnos L; Scherber R; Geyer H; Langlais BT; Dueck AC; Kosiorek HE; Senyak Z; Clark M; Boxer M; Cotter M; Harrison C; Stonnington C; Geda Y; Mesa R
Cancer Med; 2020 Nov; 9(22):8301-8309. PubMed ID: 32976697
[TBL] [Abstract][Full Text] [Related]
14. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.
Mazza GL; Kunze KL; Langlais BT; Kosiorek HE; DeWees TA; Geyer HL; Scherber RM; Mesa RA; Dueck AC
Leuk Lymphoma; 2019 Jul; 60(7):1789-1795. PubMed ID: 30652523
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese.
Guaraná M; Soares A; Daumas A; Biasoli I; Solza C
Hematol Transfus Cell Ther; 2022; 44(3):321-327. PubMed ID: 33483290
[TBL] [Abstract][Full Text] [Related]
16. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.
Scherber RM; Kosiorek HE; Senyak Z; Dueck AC; Clark MM; Boxer MA; Geyer HL; McCallister A; Cotter M; Van Husen B; Harrison CN; Mesa RA
Cancer; 2016 Feb; 122(3):477-85. PubMed ID: 26670597
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms, Related with Genetic Burden, and Thrombosis.
Ümit E; Baysal M; Kırkızlar HO; Demir AM
Turk J Haematol; 2024 May; ():. PubMed ID: 38801033
[TBL] [Abstract][Full Text] [Related]
19. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms.
Enblom A; Lindskog E; Hasselbalch H; Hersby D; Bak M; Tetu J; Girodon F; Andréasson B
Eur J Intern Med; 2015 Jun; 26(5):344-7. PubMed ID: 25863408
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients.
Cherdchoo N; Polprasert C; Rojnuckarin P; Kongkiatkamon S
Hematology; 2023 Dec; 28(1):2280731. PubMed ID: 37942783
[No Abstract] [Full Text] [Related]
[Next] [New Search]
